Dan Arias

Is that more of a placement comment or a pull-through comment? Where do you think the opportunity is strongest there?

does that assume the full $150 million of cost savings is captured this year

can you maybe talk about cost management in the current environment

how would you characterize the pharmacopeia opportunity over there that you talked about a little bit last quarter just in terms of what might be tangible

food retail was pretty strong here. Is something picking up? Or is that just sort of the inherent lumpiness of that business

to what extent do you think onshoring demand can work itself into the picture for 2026 versus 2027 and beyond

can you maybe just compare what you expect on the lab/biopharma side versus more of the industrial side

that sounds like it's now functionally $0.40 lower. Does that include some offset activities? Or is that the gross impact

does visibility into demand look like it's changing at all or at least stabilizing in some way, such that a forecast one way or another has more confidence behind it

if you were to get some de-escalation here, like, it's possible do you see the chance for some stickiness that could kind of leave the door open for a benefit

The capabilities in Mexico, I think that's through Biokix, if I remember right. It used to be Pipette tips and life sciences reagents

I just want to understand the assumptions on biopharma, which looks like it's gradually recovering here

is there any change in the way that you're feeling about industrial this year? I mean, to Patrick's point, it does seem like there's some good overall momentum in product inspection

Can you just sort of refresh us on the timing of coming to market and then what your uptake trajectory might be?

are you finding that some of the early uptick signals that you're talking about are they coming from the companies that have successfully raised money?

can you elaborate a little bit on the biotech element and just how much of the incremental enthusiasm that you might be pointing to is due to some of the larger biotech companies versus some of the...

on the GEL contributions, which I think you've kind of pointed to as being heavily weighted in in 4Q for $10 million or so, how should we model that sequentially in the quarters after that?

Can you just help us with what the ramp-up periods look like for volumes?

Can you just sort of explicitly update us on the confidence that you have in that business not getting caught up there?

Do you see yourself as being potentially acquisitive and particularly on something larger than maybe a bolt-on over the next 12 months to 18 months?

What kind of step down should we assume in the back half of the year? It seems like you're north of 20% for the first half

on consumables, how are you thinking about the pull-through rate for LUNIPOR this year? Is that something that you think can grow as an average?

does that assume that both academic and biotech are growing at that point? Or is it what gets you there really just continued pharma strength

plus 1% organic this quarter, ex the GMP customers and you're expecting the same thing next quarter ex those accounts, 3% without them

what kind of 80-20 type rule exists when it comes to these cell therapy accounts?

Can you expand on where the funding is coming from for the 2/3 of the academic customers that aren't tied to the NIH?

the EBITDA threshold could be managed to, especially since I think that's the one that's actually closer to hitting the target

Is there a growth rate for the quarter? And just given what we're talking about, about some of the fluctuations in pharma ordering patterns

what kind of growth expectations do you have for that piece next quarter?

I think that there might have been also some phasing in pharma services that was material. Is that a quantifiable amount?

I'm curious if you think there's anything that's sort of an offset there that maybe 90 days later, you're feeling a little bit better about

are you finding that that's actually translating the spending plans

Is mid singles plus the right way to think about things

what are you seeing on the research and industrial side? Is that fluid in a way that you think introduces some additional risk

I'm just curious whether demand from small and emerging biotech is getting any better from where you sit

can you just maybe expand on the extent to which it feels like the spending decisions are being influenced by the macro factors at play

just given the moving parts on the hardware side, it would be helpful to know how you see growth there in the back half

to what extent do you see [ pill ] count increases underpinning that such that you can think about an incrementally larger opportunity

Is there a margin impact that we should be mindful of there? I know in the early days, there can actually be some downward pressure

is there anything that you can say about mass spec in biopharma? And the reason I asked just because very clear that PFAS is helping LC-MS pretty significantly

to what extent do you feel like the uptake there is partly a function of or being helped by the LC replacement cycle

to what extent do you still see there being additional capacity needs in the lab based on the water testing side, in the US